Terns Pharmaceuticals, Inc.

FOSTER CITY, CA · Founded 2020 · Biotech · Acquired

Small-molecule drug candidates for oncology and obesity

Claim this profile

Follows are private to you and power your alerts

Updated · ternspharma.com

Sector
Biotech
Headquarters
FOSTER CITY, CA
Founded
2020
Latest Form D
$97.7M, Jan 2021
Total capital
$97.7M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$97.7M
1 Form D · last Jan 2021
70 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
13
27 pending · first 2024
Rank in peer group#131 of 1449

Capital timeline

2021FEDERAL ↑EQUITY ↓Cumulative $97.7M1st Form D$97.7M
2021FEDERAL ↑EQUITY ↓Cumulative $97.7M1st Form D$97.7M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$97.7M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#131 · top 9%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Bryan YoonExecutive OfficerNamed in SEC Form D filings
  • Carl Gordon, Ph.D.DirectorNamed in SEC Form D filings
  • David FellowsDirectorNamed in SEC Form D filings
  • Elise WangDirectorNamed in SEC Form D filings
  • Hongbo Lu, Ph.D.DirectorNamed in SEC Form D filings
  • Jeffrey KindlerDirectorNamed in SEC Form D filings
Show all 11 people
  • Jill QuigleyDirectorNamed in SEC Form D filings
  • Mark Vignola, Ph.D.Executive OfficerNamed in SEC Form D filings
  • Senthil SundaramDirector, Executive OfficerNamed in SEC Form D filings
  • Weidong Zhong, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Yi Shi, Ph.D.DirectorNamed in SEC Form D filings

What it has protected

USPTO · 13 granted of 40
  • PendingThyroid Hormone Receptor Beta Agonist CompoundsUSPTOApplication 19426869
  • GrantedThyroid Hormone Receptor Beta Agonist CompoundsUSPTOUS 12,528,791
  • PendingCompounds As GLP-1R AgonistsUSPTOApplication 19242909
Show all 40 patent records

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .